12 Aug 2026

Reference: CIR-2026-00000139

To all Health facilities and healthcare practitioners in Dubai's private health sector

Referring to the above subject, DHA notifies all health facilities regarding the circulars issued by the Emirates Drug Establishment for perusal and adherence to what is stated.

Circular No. (36/2026) - Voluntary Withdrawal of Oxbryta (Voxelotor) from the UAE Market

Thanks in advance for your good co-operation

 Drug Control Section

Health Regulation Sector

DHA